Genetic Predictors of Benefit to Pembrolizumab

Stopped Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• DRUG: Pembrolizumab
• DRUG: Carboplatin
• DRUG: Nab-paclitaxel
• DRUG: Pemetrexed

Sponsor

Columbia University

Collaborators

• [object Object]
• [object Object]
• [object Object]